CoChat
Sign Up
Cited by 69Immune cells in cancerCancer, Lipids, and MetabolismLipid metabolism and biosynthesis

Lipid-loaded macrophages as new therapeutic target in cancer

Open access
Marelli, Giulia, Morina, Nicolò, Portale, Federica, Pandini, Marta, Iovino, Marta, Di Conza, Giusy, Ho, Ping-Chih, Di Mitri, Diletta·2022·Journal for ImmunoTherapy of Cancer
DOI 10.1136/jitc-2022-004584PMC PMC9263925
Open this paper in CoChat — free accountOpen PDF

Abstract

Macrophages are main players of the innate immune system. They show great heterogeneity and play diverse functions that include support to development, sustenance of tissue homeostasis and defense against infections. Dysfunctional macrophages have been described in multiple pathologies including cancer. Indeed tumor-associated macrophages (TAMs) are abundant in most tumors and sustain cancer growth, promote invasion and mediate immune evasion. Importantly, lipid metabolism influences macrophage activation and lipid accumulation confers pathogenic features on macrophages. Notably, a subset of lipid-loaded macrophages has been recently identified in many tumor types. Lipid-loaded TAMs support tumor growth and progression and exert immune-suppressive activities. In this review, we describe the role of lipid metabolism in macrophage activation in physiology and pathology and we discuss the impact of lipid accumulation in macrophages in the context of cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2022-004584

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • LD accumulation in macrophages is associated with inflammatory conditions, infectious diseases, and cancer.

    “LD accumulation in macrophages is associated with several inflammatory conditions (e.g., atherosclerosis) (4, 5), infectious diseases (e.g., mycobacterial infections) (6, 7), and cancer (8, 9).”

    From Reducing microglial lipid load enhances β amyloid phagocytosis in an Alzheimer’s disease mouse model (2025) · cites this paper as [9]

  • Lipid droplet accumulation in macrophages occurs in lipid-rich microenvironments in the periphery.

    “LD accumulation in macrophages has also been documented in lipid-rich microenvironments in the peripheral, such as atherosclerosis plaques (5), white adipose tissue (10), and tumors (9).”

    From Reducing microglial lipid load enhances β amyloid phagocytosis in an Alzheimer’s disease mouse model (2025) · cites this paper as [9]

  • Lipid droplet accumulation in macrophages elevates ROS production, promoting neurovascular dysfunction.

    “LD accumulation in macrophages can elevate their ROS production (9, 11), promoting neurovascular dysfunction (67).”

    From Reducing microglial lipid load enhances β amyloid phagocytosis in an Alzheimer’s disease mouse model (2025) · cites this paper as [9]

    The 'Lipid accumulation in tumor-associated macrophages' section describes lipid droplets in macrophages but does not link them to increased ROS production. The ROS passage in Figure 2 concerns CD4+ T cells, not macrophages. I searched for ROS, reactive oxygen species, and lipid droplets in macrophages; neurovascular dysfunction is attached to a different citation in the citing sentence. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 89

  1. [1]van Eijk M, Aerts JMFG,. The unique phenotype of Lipid-Laden macrophages. Int J Mol Sci 2021; 22. 10.3390/ijms22084039. [Epub ahead of print: 14 Apr 2021]. PMC8070766 33919858 · DOI · Paper page
  2. [2]Yan J, Horng T. Lipid metabolism in regulation of macrophage functions. Trends Cell Biol 2020; 30: 979– 89. 10.1016/j.tcb.2020.09.006 33036870 · DOI
  3. [4]Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656– 61. 10.1126/science.1178331 20133564 PMC2887389 · DOI · Paper page
  4. [7]Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549– 55. 10.1016/s1471-4906(02)02302-5 12401408 · DOI · Paper page
  5. [8]Poh AR, Ernst M. Targeting macrophages in cancer: from bench to bedside. Front Oncol 2018; 8: 1– 16. 10.3389/fonc.2018.00049 29594035 PMC5858529 · DOI
  6. [9]Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23– 35. 10.1038/nri978 12511873 · DOI · Paper page
  7. [10]Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122: 787– 95. 10.1172/JCI59643 22378047 PMC3287223 · DOI · Paper page
  8. [11]Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell Metab 2012; 15: 432– 7. 10.1016/j.cmet.2011.11.013 22482726 · DOI · Paper page
  9. [12]Batista-Gonzalez A, Vidal R, Criollo A, et al. New insights on the role of lipid metabolism in the metabolic reprogramming of macrophages. Front Immunol 2019; 10: 1– 7. 10.3389/fimmu.2019.02993 31998297 PMC6966486 · DOI
  10. [13]Wculek SK, Dunphy G, Heras-Murillo I, et al. Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol Immunol 2022; 19: 384– 408. 10.1038/s41423-021-00791-9 34876704 PMC8891297 · DOI · Paper page
  11. [14]Covarrubias AJ, Aksoylar HI, Yu J, et al. Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. Elife 2016; 5: 1– 19. 10.7554/eLife.11612 PMC4769166 26894960 · DOI
  12. [15]Huang SC-C, Smith AM, Everts B, et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity 2016; 45: 817– 30. 10.1016/j.immuni.2016.09.016 27760338 PMC5535820 · DOI
  13. [16]Zhang Q, Wang J, Yadav DK, et al. Glucose metabolism: the metabolic signature of tumor associated macrophage. Front Immunol 2021; 12: 1– 9. 10.3389/fimmu.2021.702580 PMC8276123 34267763 · DOI
  14. [17]Wang F, Zhang S, Vuckovic I, et al. Glycolytic stimulation is not a requirement for M2 macrophage differentiation. Cell Metab 2018; 28: 463– 75. 10.1016/j.cmet.2018.08.012 30184486 PMC6449248 · DOI
  15. [18]M de-Brito N, Duncan-Moretti J, C da-Costa H, et al. Aerobic glycolysis is a metabolic requirement to maintain the M2-like polarization of tumor-associated macrophages. Biochim Biophys Acta Mol Cell Res 2020; 1867: 118604. 10.1016/j.bbamcr.2019.118604 31760090 · DOI
  16. [19]Lauterbach MA, Hanke JE, Serefidou M, et al. Toll-Like receptor signaling rewires macrophage metabolism and promotes histone acetylation via ATP-citrate lyase. Immunity 2019; 51: 997– 1011. 10.1016/j.immuni.2019.11.009 31851905 · DOI
  17. [20]Ameer F, Scandiuzzi L, Hasnain S, et al. De novo lipogenesis in health and disease. Metabolism 2014; 63: 895– 902. 10.1016/j.metabol.2014.04.003 24814684 · DOI
  18. [21]Wei X, Song H, Yin L, et al. Fatty acid synthesis configures the plasma membrane for inflammation in diabetes. Nature 2016; 539: 294– 8. 10.1038/nature20117 27806377 PMC5671339 · DOI
  19. [22]Im S-S, Yousef L, Blaschitz C, et al. Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metab 2011; 13: 540– 9. 10.1016/j.cmet.2011.04.001 21531336 PMC3090630 · DOI
  20. [23]Divakaruni AS, Hsieh WY, Minarrieta L, et al. Etomoxir inhibits macrophage polarization by disrupting CoA homeostasis. Cell Metab 2018; 28: 490– 503. 10.1016/j.cmet.2018.06.001 30043752 PMC6125190 · DOI
  21. [24]Nomura M, Liu J, Rovira II, et al. Fatty acid oxidation in macrophage polarization. Nat Immunol 2016; 17: 216– 7. 10.1038/ni.3366 26882249 PMC6033271 · DOI
  22. [25]Moon J-S, Nakahira K, Chung K-P, et al. Nox4-Dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages. Nat Med 2016; 22: 1002– 12. 10.1038/nm.4153 27455510 PMC5204248 · DOI · Paper page
  23. [26]Hossain F, Al-Khami AA, Wyczechowska D, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res 2015; 3: 1236– 47. 10.1158/2326-6066.CIR-15-0036 26025381 PMC4636942 · DOI
  24. [27]Niu Z, Shi Q, Zhang W, et al. Caspase-1 cleaves PPARγ for potentiating the pro-tumor action of TAMs. Nat Commun 2017; 8. 10.1038/s41467-017-00523-6 PMC5626701 28974683 · DOI
  25. [28]Park HY, Kang HS, Im S-S,. Recent insight into the correlation of SREBP-mediated lipid metabolism and innate immune response. J Mol Endocrinol 2018; 61: R123– 31. 10.1530/JME-17-0289 30307160 · DOI
  26. [29]Soyal SM, Nofziger C, Dossena S, et al. Targeting SREBPs for treatment of the metabolic syndrome. Trends Pharmacol Sci 2015; 36: 406– 16. 10.1016/j.tips.2015.04.010 26005080 · DOI
  27. [30]Chawla A. Control of macrophage activation and function by PPARs. Circ Res 2010; 106: 1559– 69. 10.1161/CIRCRESAHA.110.216523 20508200 PMC2897247 · DOI · Paper page
  28. [31]Odegaard JI, Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol 2011; 6: 275– 97. 10.1146/annurev-pathol-011110-130138 21034223 PMC3381938 · DOI · Paper page
  29. [33]Jones RG, Pearce EJ. Mentoring immunity: mTOR signaling in the development and function of tissue-resident immune cells. Immunity 2017; 46: 730– 42. 10.1016/j.immuni.2017.04.028 28514674 PMC5695239 · DOI
  30. [34]Linke M, Fritsch SD, Sukhbaatar N, et al. Mtorc1 and mTORC2 as regulators of cell metabolism in immunity. FEBS Lett 2017; 591: 3089– 103. 10.1002/1873-3468.12711 28600802 PMC6322652 · DOI
  31. [35]Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res 2019; 79: 4557– 67. 10.1158/0008-5472.CAN-18-3962 31350295 PMC6744958 · DOI · Paper page
  32. [36]Allavena P, Sica A, Solinas G, et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66: 1– 9. 10.1016/j.critrevonc.2007.07.004 17913510 · DOI · Paper page
  33. [39]Di Mitri D, Mirenda M, Vasilevska J, et al. Re-Education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep 2019; 28: 2156– 68. 10.1016/j.celrep.2019.07.068 31433989 PMC6715643 · DOI
  34. [41]Zhang Q, Cheng S, Wang Y, et al. Interrogation of the microenvironmental landscape in spinal ependymomas reveals dual functions of tumor-associated macrophages. Nat Commun 2021; 12: 1– 17. 10.1038/s41467-021-27018-9 34824203 PMC8617028 · DOI
  35. [42]Henze A-T, Mazzone M. The impact of hypoxia on tumor-associated macrophages. J Clin Invest 2016; 126: 3672– 9. 10.1172/JCI84427 27482883 PMC5096805 · DOI
  36. [43]Wenes M, Shang M, Di Matteo M, et al. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metab 2016; 24: 701– 15. 10.1016/j.cmet.2016.09.008 27773694 · DOI · Paper page
  37. [44]Certo M, Tsai C-H, Pucino V, et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol 2021; 21: 151– 61. 10.1038/s41577-020-0406-2 32839570 · DOI · Paper page
  38. [45]Geeraerts X, Fernández-Garcia J, Hartmann FJ, et al. Macrophages are metabolically heterogeneous within the tumor microenvironment. Cell Rep 2021; 37: 110171. 10.1016/j.celrep.2021.110171 34965415 · DOI
  39. [46]Colegio OR, Chu N-Q, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014; 513: 559– 63. 10.1038/nature13490 25043024 PMC4301845 · DOI · Paper page
  40. [47]Reinfeld BI, Madden MZ, Wolf MM, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 2021; 593: 282– 8. 10.1038/s41586-021-03442-1 33828302 PMC8122068 · DOI
  41. [48]Devalaraja S, To TKJ, Folkert IW, et al. Tumor-Derived retinoic acid regulates intratumoral monocyte differentiation to promote immune suppression. Cell 2020; 180: e16: 1098– 114. 10.1016/j.cell.2020.02.042 PMC7194250 32169218 · DOI
  42. [49]Di Conza G, Tsai C-H, Gallart-Ayala H, et al. Tumor-Induced reshuffling of lipid composition on the endoplasmic reticulum membrane sustains macrophage survival and pro-tumorigenic activity. Nat Immunol 2021; 22: 1403– 15. 10.1038/s41590-021-01047-4 34686867 PMC7611917 · DOI
  43. [50]Wang X, Ping F-F, Bakht S, et al. Immunometabolism features of metabolic deregulation and cancer. J Cell Mol Med 2019; 23: 694– 701. 10.1111/jcmm.13977 30450768 PMC6349168 · DOI
  44. [51]Bian X, Liu R, Meng Y, et al. Lipid metabolism and cancer. J Exp Med 2021; 218: 1– 17. 10.1084/jem.20201606 PMC7754673 33601415 · DOI
  45. [52]Chang C-H, Qiu J, O'Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 2015; 162: 1229– 41. 10.1016/j.cell.2015.08.016 26321679 PMC4864363 · DOI · Paper page
  46. [53]Borst J, Ahrends T, Bąbała N, et al. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 2018; 18: 635– 47. 10.1038/s41577-018-0044-0 30057419 · DOI · Paper page
  47. [55]Brown ZJ, Fu Q, Ma C, et al. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death Dis 2018; 9: 1– 14. 10.1038/s41419-018-0687-6 29795111 PMC5966464 · DOI
  48. [56]Chen X, Song M, Zhang B, et al. Reactive oxygen species regulate T cell immune response in the tumor microenvironment. Oxid Med Cell Longev 2016; 2016: 11– 16. 10.1155/2016/1580967 PMC4980531 27547291 · DOI · Paper page
  49. [57]Wang H, Franco F, Ho P-C,. Metabolic regulation of Tregs in cancer: opportunities for immunotherapy. Trends Cancer 2017; 3: 583– 92. 10.1016/j.trecan.2017.06.005 28780935 · DOI
  50. [58]Pacella I, Procaccini C, Focaccetti C, et al. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc Natl Acad Sci U S A 2018; 115: E6546– 55. 10.1073/pnas.1720113115 29941600 PMC6048537 · DOI
  51. [60]Miska J, Lee-Chang C, Rashidi A, et al. HIF-1α Is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of Tregs in glioblastoma. Cell Rep 2019; 27: 226– 37. 10.1016/j.celrep.2019.03.029 30943404 PMC6461402 · DOI
  52. [61]Wang H, Franco F, Tsui Y-C, et al. Cd36-Mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol 2020; 21: 298– 308. 10.1038/s41590-019-0589-5 32066953 PMC7043937 · DOI
  53. [62]McDonnell E, Crown SB, Fox DB, et al. Lipids reprogram metabolism to become a major carbon source for histone acetylation. Cell Rep 2016; 17: 1463– 72. 10.1016/j.celrep.2016.10.012 27806287 PMC5123807 · DOI
  54. [63]Lim SA, Wei J, Nguyen T-LM, et al. Lipid signalling enforces functional specialization of Treg cells in tumours. Nature 2021; 591: 306– 11. 10.1038/s41586-021-03235-6 33627871 PMC8168716 · DOI
  55. [64]Field CS, Baixauli F, Kyle RL, et al. Mitochondrial integrity regulated by lipid metabolism is a cell-intrinsic checkpoint for Treg suppressive function. Cell Metab 2020; 31: 422– 37. 10.1016/j.cmet.2019.11.021 31883840 PMC7001036 · DOI
  56. [65]Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity 2011; 35: 161– 8. 10.1016/j.immuni.2011.07.010 21867926 PMC3303224 · DOI
  57. [66]Kleinfeld AM, Okada C. Free fatty acid release from human breast cancer tissue inhibits cytotoxic T-lymphocyte-mediated killing. J Lipid Res 2005; 46: 1983– 90. 10.1194/jlr.M500151-JLR200 15961785 · DOI
  58. [67]Kado T, Nawaz A, Takikawa A, et al. Linkage of CD8+ T cell exhaustion with high-fat diet-induced tumourigenesis. Sci Rep 2019; 9: 1– 8. 10.1038/s41598-019-48678-0 31439906 PMC6706391 · DOI
  59. [68]Zhang Y, Kurupati R, Liu L, et al. Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell 2017; 32: 377– 91. 10.1016/j.ccell.2017.08.004 28898698 PMC5751418 · DOI
  60. [69]Arbore G, West EE, Rahman J, et al. Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism. Nat Commun 2018; 9: 4186. 10.1038/s41467-018-06706-z 30305631 PMC6180132 · DOI
  61. [70]Lee J, Walsh MC, Hoehn KL, et al. Regulator of fatty acid metabolism, acetyl coenzyme A carboxylase 1, controls T cell immunity. J Immunol 2014; 192: 3190– 9. 10.4049/jimmunol.1302985 24567531 PMC3965631 · DOI
  62. [72]Yang W, Bai Y, Xiong Y, et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature 2016; 531: 651– 5. 10.1038/nature17412 26982734 PMC4851431 · DOI · Paper page
  63. [74]Xu S, Chaudhary O, Rodríguez-Morales P, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity 2021; 54: 1561– 77. 10.1016/j.immuni.2021.05.003 34102100 PMC9273026 · DOI
  64. [75]Ma X, Xiao L, Liu L, et al. CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability. Cell Metab 2021; 33: 1001– 12. 10.1016/j.cmet.2021.02.015 33691090 PMC8102368 · DOI
  65. [76]Jiang L, Fang X, Wang H, et al. Ovarian Cancer-Intrinsic fatty acid synthase prevents anti-tumor immunity by disrupting tumor-infiltrating dendritic cells. Front Immunol 2018; 9: 1– 13. 10.3389/fimmu.2018.02927 30619288 PMC6302125 · DOI
  66. [77]James BR, Tomanek-Chalkley A, Askeland EJ, et al. Diet-Induced obesity alters dendritic cell function in the presence and absence of tumor growth. J Immunol 2012; 189: 1311– 21. 10.4049/jimmunol.1100587 22745381 PMC3401274 · DOI
  67. [78]Veglia F, Tyurin VA, Mohammadyani D, et al. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat Commun 2017; 8: 2122. 10.1038/s41467-017-02186-9 29242535 PMC5730553 · DOI
  68. [79]Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, et al. Er stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 2015; 161: 1527– 38. 10.1016/j.cell.2015.05.025 26073941 PMC4580135 · DOI · Paper page
  69. [80]Herber DL, Cao W, Nefedova Y, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 2010; 16: 880– 6. 10.1038/nm.2172 20622859 PMC2917488 · DOI
  70. [81]Bougnères L, Helft J, Tiwari S, et al. A role for lipid bodies in the cross-presentation of phagocytosed antigens by MHC class I in dendritic cells. Immunity 2009; 31: 232– 44. 10.1016/j.immuni.2009.06.022 19699172 PMC2803012 · DOI
  71. [83]Michelet X, Dyck L, Hogan A, et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol 2018; 19: 1330– 40. 10.1038/s41590-018-0251-7 30420624 · DOI
  72. [84]Conroy MJ, Fitzgerald V, Doyle SL, et al. The microenvironment of visceral adipose tissue and liver alter natural killer cell viability and function. J Leukoc Biol 2016; 100: 1435– 42. 10.1189/jlb.5AB1115-493RR 27365528 · DOI
  73. [85]Kaur K, Chang H-H, Topchyan P, et al. Deficiencies in natural killer cell numbers, expansion, and function at the pre-neoplastic stage of pancreatic cancer by KRAS mutation in the pancreas of obese mice. Front Immunol 2018; 9: 1– 12. 10.3389/fimmu.2018.01229 29977235 PMC6021953 · DOI
  74. [86]Wu H, Han Y, Rodriguez Sillke Y, et al. Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages. EMBO Mol Med 2019; 11: e10698. 10.15252/emmm.201910698 31602788 PMC6835560 · DOI
  75. [88]Masetti M, Carriero R, Portale F. Lipid-Loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer. J Exp Med 2022; 219(2). 10.1084/jem.20210564. [Epub ahead of print: 07 02 2022]. 34919143 PMC8932635 · DOI
  76. [89]Pombo Antunes AR, Scheyltjens I, Lodi F, et al. Single-Cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat Neurosci 2021; 24: 595– 610. 10.1038/s41593-020-00789-y 33782623 · DOI · Paper page
  77. [90]Huggins DN, LaRue RS, Wang Y, et al. Characterizing macrophage diversity in metastasis-bearing lungs reveals a lipid-associated macrophage subset. Cancer Res 2021; 81: 5284– 95. 10.1158/0008-5472.CAN-21-0101 34389631 PMC8530952 · DOI
  78. [91]Zhou L, Wang M, Guo H, et al. Integrated Analysis Highlights the Immunosuppressive Role of TREM2+ Macrophages in Hepatocellular Carcinoma. Front Immunol 2022; 13: 1– 14. 10.3389/fimmu.2022.848367 PMC8963870 35359989 · DOI · Paper page
  79. [93]Casanova-Acebes M, Menéndez-Gutiérrez MP, Porcuna J, et al. RXRs control serous macrophage neonatal expansion and identity and contribute to ovarian cancer progression. Nat Commun 2020; 11: 1655. 10.1038/s41467-020-15371-0 32246014 PMC7125161 · DOI
  80. [94]Su P, Wang Q, Bi E, et al. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res 2020; 80: 1438– 50. 10.1158/0008-5472.CAN-19-2994 32015091 PMC7127942 · DOI
  81. [95]Rabold K, Aschenbrenner A, Thiele C, et al. Enhanced lipid biosynthesis in human tumor-induced macrophages contributes to their protumoral characteristics. J Immunother Cancer 2020; 8. 10.1136/jitc-2020-000638 PMC7500191 32943450 · DOI
  82. [96]El-Kenawi A, Dominguez-Viqueira W, Liu M, et al. Macrophage-Derived cholesterol contributes to therapeutic resistance in prostate cancer. Cancer Res 2021; 81: 5477– 90. 10.1158/0008-5472.CAN-20-4028 34301759 PMC8563406 · DOI
  83. [97]Sag D, Cekic C, Wu R, et al. The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunity. Nat Commun 2015; 6: 6354. 10.1038/ncomms7354 25724068 PMC4347884 · DOI · Paper page
  84. [98]Goossens P, Rodriguez-Vita J, Etzerodt A, et al. Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab 2019; 29: 1376– 89. 10.1016/j.cmet.2019.02.016 30930171 · DOI · Paper page
  85. [99]Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov 2018; 17: 887– 904. 10.1038/nrd.2018.169 30361552 · DOI
  86. [100]Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015; 27: 462– 72. 10.1016/j.ccell.2015.02.015 25858805 PMC4400235 · DOI · Paper page
  87. [101]Park J, Lee SE, Hur J, et al. M-CSF from cancer cells induces fatty acid synthase and PPARβ/δ activation in tumor myeloid cells, leading to tumor progression. Cell Rep 2015; 10: 1614– 25. 10.1016/j.celrep.2015.02.024 25753425 · DOI
  88. [102]Palmieri EM, Menga A, Martín-Pérez R, et al. Pharmacologic or genetic targeting of glutamine synthetase skews macrophages toward an M1-like phenotype and inhibits tumor metastasis. Cell Rep 2017; 20: 1654– 66. 10.1016/j.celrep.2017.07.054 28813676 PMC5575233 · DOI
  89. [103]Su P, Wang Q, Bi E. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res 20202019; 80: canres.2994– 1450. 10.1158/0008-5472.CAN-19-2994 PMC7127942 32015091 · DOI

Cited by

Sorted by citations

Authors
Marelli, G., Morina, N., Portale, F., Pandini, M., Iovino, M., Di Conza, G., Ho, P.-C., & Di Mitri, D.
Affiliations
  • IRCCS Humanitas Research Hospital (IT)
  • Humanitas University (IT)
  • Department of Oncology, University of Lausanne, Lausanne, Switzerland
  • University of Lausanne (CH)
  • Tumor Microenvironment Unit, IRCCS Humanitas Research Hospital, Lombardia, Italy
ORCID
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2022-07
Volume
10
Issue
7
Pages
e004584
ISSN
2051-1426 (ISSN-L)
DOI
10.1136/jitc-2022-004584
PMC
PMC9263925
OpenAlex
W4284712532
Cited by
69
References
15
Citations by year
2026: 21 · 2025: 26 · 2024: 11 · 2023: 9 · 2022: 2
FWCI
1.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion, cc-by-nc)
  • IRIS (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cancer Research Institute
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (182470)
  • Associazione Italiana per la Ricerca sul Cancro (22757, 5X 1000, AIRC5x1000)
  • H2020 European Research Council (802773)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords
tumor-associated macrophages, lipid metabolism, macrophage activation, lipid accumulation, tumor immunosuppression, tumor growth and progression, innate immunity
MeSH terms
Humans, Lipids, Macrophages, Neoplasms, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review